Chieh-Shan Wu

Dr. Chieh-Shan Wu

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Polymers
Verified
Journal Article
Open access
PDF file
WLWei-Chih Lin
Wei-Chih Lin
IYI-Ting Yeh
I-Ting Yeh
ENEri Niyama
Eri Niyama
WHWan-Rou Huang
Wan-Rou Huang
Mitsuhiro EbaraMitsuhiro Ebara
Mitsuhiro Ebara
CWChieh-Shan Wu
Chieh-Shan Wu
Drug delivery systems (DDS) are commonly employed to administer drug-loaded composites to their therapeutic targets both in vitro and in vivo. Thus, we herein report the study of imiquimod-poly(ε-caprolactone) (IMQ-PCL) nanofibrous meshes for application in melanoma therapy. The preparation route employed was based on the electrospinning technique, with the melanoma cells being cultured on electrospun nanofibrous meshes to study their biocompatibility. All parameters employed, including the flow rate and polymer solution concentration, were examined to gain an improved understanding of the factors influencing the diameter and morphology of the electrospun fibre. The optimised parameters were employed to produce 12 IMQ-PCL nanofibrous meshes with diameters ranging from 100 to 900 nm to the melanoma cell viability. The relationship between the fibrous diameter and the imiquimod release profile was also determined using UV-Vis spectroscopy. In addition, similar results were obtained for the simulated imiquimod release profile obtained by COMSOL Multiphysics®. The IMQ-PCL nanofibrous meshes were found to decrease cell viability by ≥50%, with the number of cells dropping by ~10% over 48 h. As the cell viability was affected by the release of imiquimod, we believe that IMQ-PCL nanofibrous meshes are a promising drug delivery system for application in melanoma therapy.

Verified
Journal Article
Open access
PDF file
CWChien-Hui Weng
Chien-Hui Weng
CWChieh-Shan Wu
Chieh-Shan Wu
JWJian-Ching Wu
Jian-Ching Wu
MKMei-Lang Kung
Mei-Lang Kung
MWMing-Hsiu Wu
Ming-Hsiu Wu
MTMing-Hong Tai
Ming-Hong Tai
Melanoma is notoriously resistant to current cancer therapy. However, the chemoresistance mechanism of melanoma remains unclear. The present study unveiled that chemotherapy drug cisplatin induced the formation of giant cells, which exhibited enlargement in cell diameter and nucleus in mice and human melanoma cells. Giant cells were positive with melanoma maker S100 and cancer stem cell markers including ABCB5 and CD133 in vitro and in vivo. Moreover, giant cells retained the mitotic ability with expression of proliferation marker Ki-67 and exhibited multiple drug resistance to doxorubicin and actinomycin D. The mitochondria genesis/activities and cellular ATP level were significantly elevated in giant cells, implicating the demand for energy supply. Application of metabolic blockers such as sodium azide or 2-deoxy glucose abolished the cisplatin-induced giant cells formation and expression of cancer stemness markers. The present study unveils a novel chemoresistance mechanism of melanoma cells via size alteration and the anti-neoplastic strategy by targeting giant cells.

3 February 2010 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YLYuan‐Hsin Lo
Yuan‐Hsin Lo
GCGwo‐Shing Cheng
Gwo‐Shing Cheng
CHChieh‐Chen Huang
Chieh‐Chen Huang
WCWen‐Yu Chang
Wen‐Yu Chang
CWChieh-Shan Wu
Chieh-Shan Wu

Verified
Journal Article
Open access
PDF file
WTWENG WEN TSAN
WENG WEN TSAN
CWChieh-Shan Wu
Chieh-Shan Wu
Feng-Sheng WangFeng-Sheng Wang
Feng-Sheng Wang
CWChang-Yi Wu
Chang-Yi Wu
YMYi-Ling Ma
Yi-Ling Ma
MTMing-Hong Tai
Ming-Hong Tai
α-melanocyte-stimulating hormone (α-MSH) has been characterized as a novel angiogenesis inhibitor. The homeostasis of nitric oxide (NO) plays an important role in neovascularization. However, it remains unclear whether α-MSH mitigates angiogenesis through modulation of NO and its signaling pathway. The present study elucidated the function and mechanism of NO signaling in α-MSH-induced angiogenesis inhibition using cultured human umbilical vein endothelial cells (HUVECs), rat aorta rings, and transgenic zebrafish. By Griess reagent assay, it was found α-MSH dose-dependently reduced the NO release in HUVECs. Immunoblotting and immunofluorescence analysis revealed α-MSH potently suppressed endothelial and inducible nitric oxide synthase (eNOS/iNOS) expression, which was accompanied with inhibition of nuclear factor kappa B (NF-κB) activities. Excessive supply of NO donor l-arginine reversed the α-MSH-induced angiogenesis inhibition in vitro and in vivo. By using antibody neutralization and RNA interference, it was delineated that melanocortin-1 receptor (MC1-R) and melanocortin-2 receptor (MC2-R) participated in α-MSH-induced inhibition of NO production and NF-κB/eNOS/iNOS signaling. This was supported by pharmaceutical inhibition of protein kinase A (PKA), the downstream effector of MC-Rs signaling, using H89 abolished the α-MSH-mediated suppression of NO release and eNOS/iNOS protein level. Therefore, α-MSH exerts anti-angiogenic function by perturbing NO bioavailability and eNOS/iNOS expression in endothelial cells.

2 May 2021 in Biology
Verified
Journal Article
Open access
PDF file
KWKuan-Jou Wu
Kuan-Jou Wu
SLShu-Hao Li
Shu-Hao Li
JLJia-Bin Liao
Jia-Bin Liao
CCChien-Chun Chiou
Chien-Chun Chiou
CWChieh-Shan Wu
Chieh-Shan Wu
Chien-Chin ChenChien-Chin Chen
Chien-Chin Chen
Background: Purely cutaneous Rosai-Dorfman disease (RDD) is a rare histiocytic proliferative disorder limited to the skin. To date, its pathogenesis remains unclear. Owing to recent findings of specific mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway in histiocytic proliferative disorders, it provides a novel perspective on the pathomechanism of cutaneous RDD. We aim to investigate the genomic mutations in MAPK/ERK pathway in cutaneous RDD. Methods: We retrospectively recruited all cases of cutaneous RDD from two hospitals in Taiwan from January 2010 to March 2020 with the clinicopathologic features, immunohistochemistry, and treatment. Mutations of neuroblastoma RAS viral oncogene homolog (NRAS), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in MAPK/ERK pathway were investigated by the highly sensitive polymerase chain reaction with Sanger sequencing. Results: Seven patients with cutaneous RDD were recruited with nine biopsy specimens. The median age was 46 years (range: 17–62 years). Four of seven patients (57.1%) received tumor excision, while the other three chose oral and/or topical or intralesional steroids. NRAS mutation was detected in 4 of 7 cases (4/7; 51.7%), and NRAS A146T was the most common mutant point (n = 4/7), followed by NRAS G13S (n = 2/7). There is no KRAS or BRAF mutation detected. Conclusions: We report the NRAS mutation is common in cutaneous RDD, and NRAS A146T was the most frequent mutation in this cohort. Mutations in the NRAS gene can activate the RAS/MAPK signaling and have been reported to be associated with various cancers. It indicates that NRAS mutation in MAPK/ERK pathway may involve the pathogenesis of cutaneous RDD.

10 July 2018 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JWJian-Ching Wu
Jian-Ching Wu
HTHan-En Tsai
Han-En Tsai
GLGuei-Sheung Liu
Guei-Sheung Liu
CWChieh-Shan Wu
Chieh-Shan Wu
MTMing-Hong Tai
Ming-Hong Tai
Hypoxia in tumors is known to trigger the pro-survival pathways such as autophagy. Systemic proopiomelanocortin (POMC) gene therapy suppresses melanoma through apoptosis induction and neovascularization blockage. In this study, we investigated the crosstalk between autophagic and apoptotic signaling in POMC-mediated melanoma suppression. By histological and immunoblot analysis, it was shown that POMC-treated melanoma tissues exhibited the prominent LC3 immunostaining, which was correlated with reduced CD31-positive tumor vascularization. Such autophagy induction could be recapitulated in melanoma cells receiving POMC gene delivery and hypoxia-mimicking agent cobalt chloride (CoCl2). We then utilized the POMC-derived peptide α-MSH with CoCl2 to elicit the autophagy as well as apoptosis in cultured melanoma cells. To delineate the role of autophagy during cell death, application of autophagy-inducer rapamycin enhanced, whereas autophagy inhibitor 3-MA attenuated, the α-MSH-induced apoptosis in melanoma cells. Genetic silencing of ATG5, an autophagy regulator, by RNA interference perturbed the α-MSH-induced apoptosis in melanoma cells. Finally, it was delineated that α-MSH stimulated the HIF-1α signaling as well as the expression of BNIP3/BNIP3L, thereby promoting the autophagy and apoptosis in melanoma cells. Therefore, the present study unveiled a unique function of autophagy in promoting cell death during POMC-mediated melanoma suppression via α-MSH/HIF-1α/BNIP3/BNIP3L signaling pathway.